Brookfield Corp’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Brookfield Corp’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-400,000	Closed	-$410K	–	699
2021 Q1	$410K	Hold	400,000	–	–	﹤0.01%	426
2020 Q4	$276K	Buy	400,000 +367,500	+1,131%	+$783K	﹤0.01%	421
2020 Q3	$73K	Buy	+32,500	New	+$92.8K	﹤0.01%	368

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Brookfield Corp's BMY.RT Position: Q2 2021 in Review

Brookfield Corp sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q2 2021, closing a stake of 400,000 shares — an estimated $410K sold.

Brookfield Corp first reported a position in BMY.RT in Q3 2020 and held it in 3 quarters. The position peaked at $410K in Q1 2021. 8 funds tracked by Wall St. Rank hold BMY.RT as of Q2 2021.

Brookfield Corp reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q2 2021 after selling out during the quarter.
Brookfield Corp sold 400,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q2 2021, an estimated $410K.
Brookfield Corp first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 3 quarters.
Brookfield Corp's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $410K in Q1 2021.
8 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q2 2021.

Based on Brookfield Corp's 13F filing for Q2 2021, filed 17 Aug 2021.